Related Experiment Video

Updated: Feb 5, 2026

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
10:39

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Published on: April 15, 2017

13.6K

Transcriptomic Analysis Identifies the Effect of Beta-Blocking Agents on a Molecular Pathway of Contraction in the

Bettina Heidecker1, Michelle M Kittleson2, Edward K Kasper3

  • 1University of California, San Francisco, California.

JACC. Basic to Translational Science
|September 1, 2018
PubMed

Insights

Beta-blockers are vital for heart failure, but predicting patient response remains challenging. This study identifies a transcriptomic biomarker to personalize beta-blocker therapy and understand its molecular effects.

Area of Science:

  • Cardiovascular Medicine
  • Genomics
  • Pharmacology

Background:

  • Beta-blockers are a cornerstone of heart failure treatment.
  • Current methods cannot predict individual patient response to beta-blockers.
  • Understanding molecular mechanisms of beta-blocker action is crucial for developing targeted therapies.

Purpose of the Study:

  • To identify patients who will benefit from beta-blocker therapy.
  • To elucidate the molecular pathways affected by beta-blockers in heart failure.
  • To develop a predictive biomarker for beta-blocker response.

Main Methods:

  • Comprehensive transcriptomic analysis of molecular pathways.
  • Identification and validation of a transcriptomic biomarker.
  • Analysis of gene expression patterns in response to beta-blocking agents.

Main Results:

  • Detailed transcriptomic profiling reveals key molecular pathways influenced by beta-blockers.
  • A novel transcriptomic biomarker capable of predicting patient response to beta-blocker therapy was identified.
  • Insights into the molecular mechanisms underlying beta-blocker efficacy in heart failure.

Conclusions:

  • Transcriptomic analysis offers a pathway to personalized medicine for heart failure.
  • The identified biomarker can guide clinical decisions regarding beta-blocker therapy.
  • Further understanding of molecular mechanisms will enable the design of novel, targeted heart failure treatments.
Keywords:
AR, adrenergic receptorEF, ejection fractionEMB, endomyocardial biopsyGO, gene ontologyHF, heart failureMYH, myosin heavy chainMiPP, Misclassified Penalized PosteriorsSAM, significance analysis of microarraysSERCA, sarcoplasmic reticulum calcium-dependent ATPaseTBB, transcriptomic-based biomarkerbeta-blocking agentsbiomarkergene expressionheart failuretranscriptomics

More Related Videos

Semi-automated Optical Heartbeat Analysis of Small Hearts12:10

Semi-automated Optical Heartbeat Analysis of Small Hearts

Published on: September 16, 2009

12.8K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.8K

Related Concept Videos

Predicting Molecular Geometry02:27

Predicting Molecular Geometry

VSEPR Theory for Determination of Electron Pair Geometries
46.0K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.5K
Molecular Orbital Theory II03:51

Molecular Orbital Theory II

Molecular Orbital Energy Diagrams
27.5K
Muscle Contraction01:15

Muscle Contraction

 
96.3K
Muscle Contraction01:10

Muscle Contraction

In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
8.9K